Article info
PDFViewpoint
Gatekeeping hormone replacement therapy for transgender patients is dehumanising
- Correspondence to Florence Ashley, Faculty of Law, McGill University, Montréal H3A 1W9, Canada; florence.pare{at}mail.mcgill.ca
Citation
Gatekeeping hormone replacement therapy for transgender patients is dehumanising
Publication history
- Received December 4, 2018
- Revised January 26, 2019
- Accepted February 4, 2019
- First published April 15, 2019.
Online issue publication
August 02, 2019
Article Versions
- Previous version (15 April 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Responding to objections to gatekeeping for hormone replacement therapy
- Reply to ‘ Hormone replacement therapy: informed consent without assessment? ’
- Hormone replacement therapy: informed consent without assessment
- International clinical practice guidelines for gender minority / trans people: systematic review and quality assessment
- Transgender patients: considerations for routine gynecologic care and cancer screening
- Comfortable in their bodies: the rise of transgender care
- Gender dysphoria: assessment and management for non-specialists
- Long term hormonal treatment for transgender people
- Trans people 's reproductive options and outcomes
- Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people